NAFDAC Bans Dove Beauty Cream Bar Soap Over Chemical Impurity Concerns

NAFDAC Recalls Dove Beauty Cream Bar Soap Due to Chemical Impurity

“These products are also not available in the NAFDAC database...”

NAFDAC recalls Dove Beauty Cream Bar Soap due to chemical impurity, poses health risks. Reports of skin sensitization and allergic reactions prompt regulatory action.

National Agency for Food and Drug Administration and Control (NAFDAC) has issued a recall for Dove Beauty Cream Bar Soap (100g) with batch number 81832M 08, manufactured in Germany, due to the detection of a chemical impurity.

The agency found that the product contains Butylphenyl Methylpropional (Lilial), a chemical linked to significant health risks, violating the Cosmetic Products Regulation.

NAFDAC announced on September 9 that Butylated Methylhydroxyanisole (BMHCA) has been banned in cosmetic products due to its potential to harm the reproductive system and pose risks to unborn children.

The statement read, “The National Agency for Food and Drug Administration and Control (NAFDAC) is alerting the public about the recall of Dove Beauty Cream Bar Soap (100g) with batch number 81832M 08, produced in Germany, due to chemical impurity.

It said, “Importation of soaps is prohibited in Nigeria as per the restricted and import prohibition list. Beyond the import restrictions soaps and cosmetics are parts of the items ineligible for foreign exchange to import in Nigeria.

“These products are also not available in the NAFDAC database. Importers, distributors, retailers and consumers are advised to exercise caution and vigilance within the supply chain to avoid the importation, distribution, sale and use of the above-mentioned products.

“Members of the public in possession of the product should discontinue the sale or use and submit stock to the nearest NAFDAC office.”

NAFDAC urges healthcare professionals to report any adverse reactions or side effects related to the use of regulated products to their local NAFDAC office.

The statement added, “Healthcare professionals and consumers are encouraged to report adverse events experienced with the use of regulated products to the nearest NAFDAC office, via pharmacovigilance@nafdac.gov.ng, E- reporting platforms available at www.nafdac.gov.ng or via the Med-safety application for download on android and IOS stores.”